By Robert Chapman — 2019
Can neurodiversity proponents keep the notion of mental pathology?
Read on www.psychologytoday.com
CLEAR ALL
The drug known by the street names Ecstasy or Molly could be a promising treatment for post-traumatic stress disorder, according to a new study.
Edith Eger, an Auschwitz survivor and psychologist, predicts nurses and doctors will experience PTSD because of the pandemic.
For nearly 20 years the idea of using virtual reality to treat PTSD has been gaining momentum. But new breakthroughs in the platform are making it easier and more affordable than ever for veterans to find help.
Because PTSD is a natural response to danger, it’s almost unavoidable in the short term and mostly self-correcting in the long term. Only about 20 percent of people exposed to trauma react with long-term (chronic) PTSD.
Post-traumatic stress disorder can happen to a person after experiencing a traumatic event that has caused them to feel fearful, shocked, or helpless. It can have long-term effects, including flashbacks, difficulty sleeping, and anxiety.
People who develop post-traumatic stress disorder (PTSD) also commonly experience guilt. In particular, individuals who have endured traumatic events may also begin to feel what’s known as trauma-related guilt. But what does the term mean exactly?
1
Williams is the co-lead author of a recent retrospective study that found those who tried doses of psilocybin (more commonly known as magic mushrooms), LSD, or MDMA (the pure substance found in Ecstasy or Molly) reported a decrease in trauma symptoms, depression and anxiety after 30 days.
Obsessive-compulsive disorder (OCD) is usually treated as a stand-alone mental illness. A growing body of research is now finding that some cases of OCD may stem from trauma.
Post-traumatic stress disorder (PTSD) and eating disorders often co-occur. People with eating disorders may have other mental health conditions, such as generalized anxiety disorder, social anxiety disorder, or obsessive-compulsive disorder (OCD).
The Food and Drug Administration (FDA) has approved the design of two Phase 3 clinical trials of MDMA for treating PTSD, according to the Multidisciplinary Association for Psychedelic Studies (MAPS), which is funding and leading the clinical trials.